Anders Jack reported option exercise involving 19,850 shares of Revolution Medicines, Inc. at $18.56 for $368k on Nov 11, 2026

Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Chief Financial Officer
Chief Financial Officer
Filed Nov 13, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
$368,416Shares × reported price
Shares traded
19,850Common Stock
Price per share
$18.56Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
154,966Direct
Trade date
Nov 11, 2026Option exercise
Filed
Nov 13, 2026, 6:00 PM ET2-day reporting delay
Accession
0001193125-26-461145Code M · Transaction 401216
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Nov 11, 2026Sell3,499$181.04−$633,466.31Trade 401217
Nov 11, 2026Sell5,776$182.09−$1,051,752.42Trade 401218
Nov 11, 2026Sell2,700$182.87−$493,750.08Trade 401219
Nov 11, 2026Sell1,900$184.02−$349,646.74Trade 401220
Nov 11, 2026Sell800$185.04−$148,029.04Trade 401221
Nov 11, 2026Sell400$186.41−$74,565.52Trade 401222
Nov 11, 2026Sell600$187.34−$112,402.26Trade 401223
Nov 11, 2026Sell200$189.17−$37,834Trade 401224
Nov 11, 2026Sell500$190.99−$95,497Trade 401225
Nov 11, 2026Sell9,486$191.94−$1,820,743.79Trade 401226
Nov 11, 2026Sell9,889$192.84−$1,907,000.69Trade 401227
Nov 11, 2026Option exercise15,900$42.45$674,955Trade 401215
Nov 11, 2026Option exercise15,900$42.45−$674,955Trade 401228
Nov 11, 2026Option exercise19,850$18.56−$368,416Trade 401229
15 transaction rows in this filing. Joint filers share the same rows.

RVMD price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
RVMD · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Nov 20, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago +13%1w ago +16%1d ago +12%
Returns since7d30d90d180d1y

Footnotes in full

F1: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 12, 2026. F2: The transaction was executed in multiple trades at prices ranging from $180.50 to $181.45, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3: The transaction was executed in multiple trades at prices ranging from $181.51 to $182.50, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F4: The transaction was executed in multiple trades at prices ranging from $182.56 to $183.51, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F5: The transaction was executed in multiple trades at prices ranging from $183.59 to $184.56, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F6: The transaction was executed in multiple trades at prices ranging from $184.59 to $185.40, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F7: The transaction was executed in multiple trades at prices ranging from $185.96 to $186.68, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F8: The transaction was executed in multiple trades at prices ranging from $186.99 to $187.62, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F9: The transaction was executed in multiple trades at prices ranging from $190.43 to $191.34, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F10: The transaction was executed in multiple trades at prices ranging from $191.44 to $192.43, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F11: The transaction was executed in multiple trades at prices ranging from $192.44 to $193.37, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F12: Includes 43,650 restricted stock units. F13: Fully vested.